Roivant Sciences Ltd.
ROIV
$11.36
$0.2752.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.19% | -40.27% | -29.51% | -41.05% | -46.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.19% | -40.27% | -29.51% | -41.05% | -46.62% |
| Cost of Revenue | 26.39% | 55.51% | 31.59% | 17.32% | 7.28% |
| Gross Profit | -29.48% | -57.61% | -30.40% | -18.42% | -8.28% |
| SG&A Expenses | 49.85% | 57.47% | 18.02% | -8.38% | -19.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.38% | 9.29% | -9.00% | -21.97% | -28.69% |
| Operating Income | -39.42% | -12.39% | 7.82% | 20.79% | 27.67% |
| Income Before Tax | -114.92% | -112.41% | 654.62% | 610.10% | 536.86% |
| Income Tax Expenses | 124.03% | -125.37% | 430.57% | 377.41% | 139.37% |
| Earnings from Continuing Operations | -116.05% | -112.33% | 645.04% | 603.15% | 531.10% |
| Earnings from Discontinued Operations | 218.37% | 225.43% | 40.84% | -73.61% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 56.94% | 97.17% | 48.84% | 28.16% | 48.66% |
| Net Income | -103.95% | -102.61% | 589.95% | 588.74% | 531.00% |
| EBIT | -39.42% | -12.39% | 7.82% | 20.79% | 27.67% |
| EBITDA | -42.31% | -12.36% | 8.09% | 21.75% | 29.00% |
| EPS Basic | -104.46% | -102.48% | 554.70% | 541.28% | 476.90% |
| Normalized Basic EPS | -12.76% | 10.31% | 40.57% | 44.03% | 43.68% |
| EPS Diluted | -105.00% | -102.84% | 527.07% | 514.13% | 452.32% |
| Normalized Diluted EPS | -14.02% | 9.14% | 41.47% | 44.78% | 44.31% |
| Average Basic Shares Outstanding | -7.40% | -1.51% | 4.03% | 7.77% | 11.03% |
| Average Diluted Shares Outstanding | -8.67% | -2.91% | 5.51% | 9.29% | 12.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |